ClariCore System Used in Transrectal Ultrasound Guided Prostate Biopsy for Real-Time Tissue Evaluation

The purpose of this study is to collect information on prostate biopsies using the ClariCore
System. The ClariCore System is designed to improve how the biopsies are being collected from
the prostate by using light sensors (fiber optics) that can see changes in the prostate
tissue. Researchers will study the information collected from the light sensors to study a
method that has been developed to tell the difference between normal and suspicious (possibly
cancerous) prostate tissue during the biopsy. This information will be given to the doctor in
real-time. From this study, researchers hope to learn if this method can tell the difference
between normal and suspicious prostate tissue, and if this can improve the evaluation of
prostate tissue (biopsies).

Inclusion Criteria:

- Males > 22 years old

- Patient scheduled for TRUS-guided prostate biopsy based on standard of care urologic
requirements to assess for tissue malignancy (abnormal Digital Rectum Examination,
Prostate Specific Antigen kinetics, age, ethnicity, family history, etc.)

- Enrolling physician must have expectation that prostate dimensions will meet minimum
prostate volume and height requirements that will be evaluated at start of biopsy
procedure (i.e., Prostate volume > 20cc and height at least 22mm)

- Patient signs an Institutional Review Board approved, Informed Consent form to
participate in the study prior to any study mandated determinations or procedure

Exclusion Criteria:

- Any anatomical or co-morbidity contraindications to TRUS prostate biopsy

- Acute painful perianal disorder (i.e. rectal abscess)

- Symptomatic, acute prostatitis

- Surgical absence of a rectum or the presence of a rectal fistula

- Patient has systemic infection or evidence of any surgical site infection (superficial
or organ space), including active urinary tract infection

- Previous prostate intervention [Transurethral Prostatectomy (TURP) (bipolar,
monopolar, laser)], Transurethral Microwave Thermotherapy (TUMT), High-Intensity
Focused Ultrasound (HIFU), Cryo, Rezum, Urolift], not including previous prostate
biopsy

- Current use of blood thinning agents for medical comorbidity which prohibits the
cessation of use as typically required per standard of care (SOC) or history of a
bleeding disorder (e.g. coagulopathy)

- Prior pelvic irradiation

- Actively receiving therapy for the treatment of cancer (except for patients on 5-alpha
reductase inhibitors, or non-melanoma skin cancers that are managed nonsystemically)

- Actively receiving intravesical therapy or within 6 months of treatment for bladder
cancer

- Patient has compromised immune system

- Active inflammatory bowel disease within the last 6 months

- Any condition, or history of illness or surgery that, in the opinion of the
Investigator, might confound the results of the study or pose additional risks to the
patient (e.g. significant cardiovascular conditions or allergies)

- Patient is not likely to comply with the protocol or follow up evaluation

- Patient is participating in a clinical trial of another investigational drug or device
that may impact participation in this clinical study

- Patient is unable to provide legal Informed Consent